|
gptkbp:instanceOf
|
gptkb:antibiotic
glycopeptide antibiotic
|
|
gptkbp:activeIn
|
gptkb:Staphylococcus_aureus
gptkb:Streptococcus_pyogenes
gptkb:Streptococcus_agalactiae
Enterococcus faecalis (vancomycin-susceptible)
Streptococcus anginosus group
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2014
|
|
gptkbp:ATCCode
|
J01XA04
|
|
gptkbp:brand
|
Dalvance
Xydalba
|
|
gptkbp:CASNumber
|
171500-79-1
|
|
gptkbp:chemicalFormula
|
C88H100Cl2N10O28
|
|
gptkbp:contraindication
|
hypersensitivity to glycopeptides
|
|
gptkbp:developedBy
|
gptkb:Durata_Therapeutics
|
|
gptkbp:discoveredBy
|
Vicuron Pharmaceuticals
|
|
gptkbp:drugClass
|
antibacterial
|
|
gptkbp:eliminatedIn
|
renal and non-renal
|
|
gptkbp:excretion
|
urine and feces
|
|
gptkbp:form
|
powder for solution for infusion
|
|
gptkbp:halfLife
|
147-258 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dalbavancin
|
|
gptkbp:indication
|
methicillin-resistant Staphylococcus aureus (MRSA) infections
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Allergan
gptkb:Almirall
|
|
gptkbp:mechanismOfAction
|
inhibits cell wall synthesis
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
1816.7 g/mol
|
|
gptkbp:notEffectiveAgainst
|
Gram-negative bacteria
|
|
gptkbp:origin
|
semisynthetic derivative of A40926
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
not recommended unless necessary
|
|
gptkbp:proteinBinding
|
93%
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
pruritus
rash
|
|
gptkbp:spectrumOfActivity
|
Gram-positive bacteria
|
|
gptkbp:synonym
|
BI 397
dalbavancin hydrochloride
|
|
gptkbp:usedFor
|
acute bacterial skin and skin structure infections
|
|
gptkbp:bfsParent
|
gptkb:Glycopeptides
|
|
gptkbp:bfsLayer
|
5
|